Published in J Mol Diagn on July 01, 2007
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 3.15
Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol (2010) 3.03
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer (2008) 2.87
PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia (2008) 2.82
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology (2009) 2.56
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology (2008) 1.99
Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol (2013) 1.95
Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol (2008) 1.88
Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia (2007) 1.85
Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol (2009) 1.84
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch (2009) 1.67
STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res (2011) 1.62
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch (2007) 1.57
Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut (2007) 1.53
Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer (2010) 1.50
Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res (2008) 1.48
HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol (2010) 1.48
Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer (2010) 1.48
Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn (2010) 1.47
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. Clin Cancer Res (2015) 1.46
Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43
Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res (2013) 1.42
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res (2009) 1.39
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia (2009) 1.39
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol (2010) 1.38
18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer (2007) 1.36
DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res (2009) 1.33
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 1.33
Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer (2010) 1.32
Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One (2011) 1.32
Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol (2009) 1.26
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer (2011) 1.20
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol (2009) 1.19
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut (2015) 1.17
Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol (2011) 1.16
MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control (2010) 1.16
CIMP and colon cancer gets more complicated. Gut (2007) 1.16
The CpG island methylator phenotype in colorectal cancer. J Mol Diagn (2007) 1.15
Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther (2012) 1.13
Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol (2008) 1.13
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology (2014) 1.13
Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology (2008) 1.12
Tumor TP53 expression status, body mass index and prognosis in colorectal cancer. Int J Cancer (2011) 1.12
CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. Int J Cancer (2010) 1.11
JC virus T-antigen in colorectal cancer is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia (2009) 1.10
The MLH1 -93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosomes Cancer (2008) 1.10
Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. BMC Cancer (2010) 1.09
Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One (2010) 1.08
Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer (2012) 1.07
Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control (2010) 1.04
A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol (2009) 1.03
A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. Cancer Epidemiol Biomarkers Prev (2008) 1.03
A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res (2009) 1.02
Interpretation of genome-wide infinium methylation data from ligated DNA in formalin-fixed, paraffin-embedded paired tumor and normal tissue. BMC Res Notes (2012) 1.02
Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol (2014) 1.02
A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev (2009) 1.02
Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology (2010) 1.01
B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PLoS One (2011) 1.01
Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.01
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer (2010) 0.99
CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev (2009) 0.99
IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Neoplasia (2007) 0.98
The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer (2009) 0.96
Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.96
Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) (2011) 0.95
Important molecular genetic markers of colorectal cancer. Oncotarget (2016) 0.94
CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn (2009) 0.94
Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. Cancer Epidemiol Biomarkers Prev (2015) 0.94
Genome-wide epigenetic modifications in cancer. Prog Drug Res (2011) 0.93
Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Mod Pathol (2013) 0.92
Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int (2015) 0.92
Identification of novel hypermethylated genes and demethylating effect of vincristine in colorectal cancer. J Exp Clin Cancer Res (2014) 0.92
PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev (2010) 0.92
CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest (2016) 0.92
Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis (2012) 0.90
Molecular alterations associated with liver metastases development in colorectal cancer patients. Br J Cancer (2011) 0.90
Comparison of CpG island methylator phenotype (CIMP) frequency in colon cancer using different probe- and gene-specific scoring alternatives on recommended multi-gene panels. PLoS One (2014) 0.89
The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench (2013) 0.89
DNA methylation changes in ex-adenoma carcinoma of the large intestine. Virchows Arch (2010) 0.89
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. Clin Gastroenterol Hepatol (2016) 0.88
TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One (2011) 0.86
Annex to Quirke et al. Quality assurance in pathology in colorectal cancer screening and diagnosis: annotations of colorectal lesions. Virchows Arch (2011) 0.86
Stratification and Prognostic Relevance of Jass's Molecular Classification of Colorectal Cancer. Front Oncol (2012) 0.84
Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. Mod Pathol (2016) 0.84
Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications. Microarrays (Basel) (2015) 0.84
Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer (2016) 0.83
The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis. J Cancer (2016) 0.82
TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer. J Cancer Res Clin Oncol (2014) 0.82
MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res (2015) 0.82
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res (2000) 9.30
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
CpG island methylator phenotype in cancer. Nat Rev Cancer (2004) 7.13
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Genetic predisposition to colorectal cancer. Nat Rev Cancer (2004) 3.92
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology (2002) 3.70
Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res (2001) 3.70
CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res (1999) 3.66
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A (2000) 3.65
Cancer epigenetics. Hum Mol Genet (2005) 3.63
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol (2006) 2.80
Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am J Pathol (1999) 2.62
Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol (2004) 2.27
Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell (2003) 2.24
Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol (2005) 2.08
CIMP, at last. Gastroenterology (2005) 1.74
The incidence of Lynch syndrome. Fam Cancer (2005) 1.56
Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology (2006) 1.38
Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst (2005) 1.30
TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol (2007) 1.27
Colorectal cancer "methylator phenotype": fact or artifact? Neoplasia (2005) 1.13
Senescence and serration: a new twist to an old tale. J Pathol (2006) 0.95
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet (2008) 16.25
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst (2006) 7.19
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Powerful SNP-set analysis for case-control genome-wide association studies. Am J Hum Genet (2010) 6.60
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med (2006) 5.24
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol (2010) 4.83
ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet (2008) 4.57
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet (2012) 4.41
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
The PhenX Toolkit: get the most from your measures. Am J Epidemiol (2011) 4.19
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Genome-wide association study of circulating vitamin D levels. Hum Mol Genet (2010) 4.07
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06
Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Association of nut consumption with total and cause-specific mortality. N Engl J Med (2013) 3.94
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. Ann Intern Med (2009) 3.68
Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature (2012) 3.54
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst (2004) 3.49
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature (2011) 3.37
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Patients' perceptions of quality of care for colorectal cancer by race, ethnicity, and language. J Clin Oncol (2005) 3.30
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol Genet (2010) 3.24
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Relation of hospital volume to colostomy rates and survival for patients with rectal cancer. J Natl Cancer Inst (2003) 3.21